Latest Feature

CardioMEMS took 11 years to pay off, but for Boston Millennia it was worth it

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

Podcast: Haemonetics CEO Brian Concannon at MassDevice.com's DeviceTalks

Haemonetics CEO Brian Concannon discusses how the company will transform blood management in the coming years at MassDevice.com's DeviceTalks Boston event.

Calhoun Vision aims to disrupt ophthalmology with its light-adjustable lens

Calhoun Vision CEO Verne Sharma tells MassDevice.com why his company's light-adjustable lens will disrupt the practice of ophthalmology.

Silicon Valley in-depth: Unraveling arrhythmia with iRhythm CEO Kevin King

Kevin King, CEO of Silicon Valley digital health company iRhythm, tells MassDevice about the promise of Big Data and how remote patient monitoring can reveal intricate details of the habits of the heart.

Podcast: Covidien's Enxing Seng talks Medtronic merger, future of medicine at De

Covidien's Stacy Enxing Seng speaks to MassDevice.com about the Medtronic merger during our DeviceTalks Minnesota event.

Subscribe to the MassDevice
Newsletter
Enter your email:

Need Medtech news in a minute? We Deliver!


MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

Ex-CEO Pignatelli backs down, but not out, in spat with Biolase

August 1, 2014 by Arezu Sarvestani

Scorned Biolase ex-CEO Federico Pignatelli withdraws his lawsuit as the company urges shareholders to welcome new leadership and deny his bid for re-election to the board.

Pignatelli backs down in spat with Biolase

Former Biolase (NSDQ:BIOL) CEO Federico Pignatelli agreed this week to withdraw his lawsuit against the dental devices maker, but he's still pursuing his personal investigation into the company's recent conduct.

Hologic swings to Q3 black

August 1, 2014 by Brad Perriello

Hologic swings to fiscal 3rd-quarter profits despite flat sales growth and raises its sales and earnings forecasts for the rest of fiscal 2014.

Hologic swings to Q3 black

Hologic (NSDQ:HOLX) swung to 3rd-quarter black during the 3 months ended June 28, despite flat sales growth of just 1%, and boosted its outlook for the rest of its fiscal year.

UPDATE: FDA panel votes against Edap's ultrasound prostate cancer ablation

July 31, 2014 by Ingrid Mezo

An FDA advisory panel votes that French device maker Edap failed to demonstrate that its novel Ablatherm prostate cancer treatment is safe and effective.

UPDATE: FDA panel votes against Edap's ultrasound prostate cancer ablation

Baxter sheds vaccines biz for $635M

July 31, 2014 by Arezu Sarvestani

Illinois healthcare giant Baxter sells its commercial vaccines division ahead of a larger transformation that will split its medical products and pharmaceuticals businesses into separate entities.

`Baxter sheds vaccines biz for $635M

Baxter (NYSE:BAX) agreed to offload its commercial vaccines business to pharmaceutical rival Pfizer (NYSE:PFE) for $635 million in cash.

Report: Medtech M&A exits don't hinge on FDA approval

July 31, 2014 by Arezu Sarvestani

Medical device startups face significant headwinds in finding funding and getting to an exit, but at least prospective buyers are a little more willing to gamble on companies that haven't yet made it through the FDA.

Report: Medtech M&A no longer hinges on FDA approval

The funding environment for medical device startups isn't a pretty scene, but there is a ray of sunshine through the gloom: lack of FDA approval is no longer a deal-breaker for a big exit.

In 2013 a few medtech companies managed "big exit M&A" deals (those worth $50 million or more) without having reached the FDA's brass ring, according to a new report from Silicon Valley Bank.

MassDevice.com +3 | The top 3 medtech stories for July 31, 2014

July 31, 2014 by MassDevice

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

 

Smith & Nephew shifts jobs to China

July 31, 2014 by Arezu Sarvestani

Smith & Nephew confirms that it's cutting some of its U.K. manufacturing jobs and moving the positions to a plant in China.

Smith & Nephew shifts jobs to China

Strong Q2 can't buoy HeartWare as shares sink on recall news

July 31, 2014 by Brad Perriello

A voluntary recall initiated yesterday pushes HeartWare shares down today, despite 2nd-quarter result that crushed expectations on Wall Street.

Strong Q2 can't buoy HeartWare after recall news

UPDATED July 31, 2014 with additional comment on recall.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp